Weekly Analysts’ Ratings Updates for MediciNova (MNOV)

Several analysts have recently updated their ratings and price targets for MediciNova (NASDAQ: MNOV):

• 12/17/2024 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/9/2024 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/2/2024 – MediciNova is now covered by analysts at D. Boral Capital. They set a “buy” rating and a $9.00 price target on the stock.
• 12/1/2024 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/23/2024 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/15/2024 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/7/2024 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/30/2024 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 10/22/2024 – MediciNova is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

MediciNova Stock Up 0.9 %

Shares of NASDAQ MNOV traded up $0.02 during midday trading on Friday, hitting $2.18. The stock had a trading volume of 20,964 shares, compared to its average volume of 49,146. The business’s 50 day moving average is $1.93 and its 200-day moving average is $1.65. MediciNova, Inc. has a 52 week low of $1.12 and a 52 week high of $2.55. The company has a market cap of $106.92 million, a P/E ratio of -10.38 and a beta of 0.84.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in MediciNova stock. Jane Street Group LLC bought a new stake in MediciNova, Inc. (NASDAQ:MNOV) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,138 shares of the biopharmaceutical company’s stock, valued at approximately $30,000. Institutional investors and hedge funds own 9.90% of the company’s stock.

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.